Xoma/Sanofi patent agreement
Executive Summary
Companies settle litigation over ricin A chain immunotoxin technology with agreement to share exclusive rights to ricin A technology covered by Sanofi patents. In return, Xoma will pay Sanofi royalties on products incorporating such technology. Xoma products that may be covered by Sannofi's patents are XomaZyme-Mel, XomaZyme-791 and XomaZyme-H65. Litigation began in November 1987, when Sanofi filed a patent infringement suit against Xoma.